Lung cancer is the leading cause of cancer deaths worldwide ([@bib3]). Although lung cancer is predominantly preventable (the main cause being nicotine), it causes more than one million cancer-related deaths per year worldwide. Unfortunately, only 15% of lung cancer patients survive for more than 5 years from the time of diagnosis ([@bib29]; [@bib7]).

The most common type of lung cancer (about 85%) is the non-small-cell lung cancer (NSCLC) and the main histological subtypes among NSCLC are adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma, respectively. Squamous cell carcinoma represents 20--30% of NSCLC and is strongly associated with cigarette smoking. However, lung ADC is the most common subtype of NSCLC (40%) in many countries. It has an increased incidence in smokers, but it is also the most common type of lung cancer in non-smokers and women ([@bib8]).

Interferons are a group of pleiotropic cytokines that have an important role during innate and acquired immune responses and host defence against viral and mycobacterial infections as well as in tumour immune surveillance ([@bib24]). Some well-described anti-tumour effects of IFN-*γ* are upregulation of MHC class I molecules and thus antigen presentation, leading to increased tumour cell recognition and elimination. This effect has been attributed to immune responses mediated by type 1 T helper (Th1) cells and type 1 cytotoxic (Tc1) cells or cytotoxic T lymphocytes (CTLs), which both secrete IFN-*γ*. T-bet drives IFN-*γ* production in Th1 and Tc1 cells and is also able to redirect Th2 cells into the Th1 pathway ([@bib27]). We previously described that T-bet-deficient mice have increased lung tumour load as compared with wild-type littermates ([@bib25]).

In this project, we analysed the signature markers of Th1 and Tc1 cells as well as their function in NSCLC in lung regions near and distant from the tumour cells.

Materials and methods
=====================

Human subjects and study population
-----------------------------------

This study was performed at the Friedrich-Alexander-University of Erlangen in Germany and was approved by the ethics review board of the University of Erlangen (Re-No: 56_12B; DRKS-ID: DRKS00005376). Thirty-seven patients, who were suffering from NSCLC, underwent surgery and gave their approval to being enrolled in this study. Patients\' confidentiality was maintained.

The diagnosis of lung cancer was based on pathological confirmation. The histological types of lung cancer were classified according to the classification of the World Health Organization, formulated in 2004. The staging of lung cancer was based on the Cancer TNM Staging Manual, formulated by the International Association for the Study of Lung Cancer in 2010.

Tissue samples were taken from the tumoral area (solid tumour tissue), the peri-tumoral area (up to 2 cm away from the solid tumour) as well as from the tumour-free control area (at least 5 cm away from the solid tumour) of the surgically removed lung material.

Total cell isolation
--------------------

Samples were cut into very small pieces using scalpels (1--3 mm^2^). The shredded material was then subjected to collagenase/DNase digestion (20 ml solution per 1 g of material) and incubated overnight at 37 °C under constant shaking (300 r.p.m). The digestion solution contained 4.8 *μ*g ml^−1^ collagenase (Liberase TM Research Grade REF 05 401 119 001, Roche Diagnostics, Mannheim, Germany) and 15 *μ*g ml^−1^ DNase (Roche Diagnostics), dissolved in PBS. To get a single-cell suspension, the digested material was sieved through a cell strainer (70 *μ*m). The cell suspension was centrifuged (10 min, 1000 r.p.m., 4 °C) and the supernatant was discarded. The cells were resuspended in 10 ml of hypotonic solution (Ammonium-Chloride-Potassium buffer) and immediately centrifuged again (5 min, 1000 r.p.m., 4 °C) to quickly remove the Ammonium-Chloride-Potassium lysis buffer. This was followed by cell resuspension in 10 ml of PBS+EDTA+1% penicilin/streptomycin and centrifugation (10 min, 1000 r.p.m., 4 °C). Cells were finally resuspended in PBS+EDTA+1% penicilin/streptomycin+5% FCS.

Quantitative real-time PCR
--------------------------

Total RNA was extracted from frozen tissue samples or from cell suspension samples, using peqGold RNA Pure (Peqlab, Erlangen, Germany) according to the manufacturer\'s instructions. One microgram of the resulting RNA was reverse-transcribed into cDNA via the RevertAid First Strand cDNA Synthesis Kit (Fermentas, St Leon-Rot, Germany) according to the manufacturer\'s protocol. Each quantitative real-time PCR reaction mix contained 15 ng of cDNA, 300 nM transcript-specific forward and reverse primer and 2 × SoFast EvaGreen Supermix (Bio-Rad, Munich, Germany) in a total volume of 20 *μ*l. Quantitative real-time PCR primers were purchased from Eurofins-MWG-Operon (Ebersberg, Germany). The primer sequences are given for *HPRT* (fw: 5′-TGACACTGGCAAAACAATGCA-3′ rev: 5′- GGTCCTTTTCACCAGCAAGCT-3′), *TBX21* (fw: 5′- CAGAATGCCGAGATTACTCAG-3′ rev: 5′- GGTTGGGTAGGAGAGGAGAG-3′), *IFNG* (fw: 5′- CATGTATTGCTTTGCGTTGG-3′ rev: 5′-TGACCAGAGCATCCAAAAGA-3′), *PRF1* (fw: 5′-GGACCAGTACAGCTTCAGCACTG- 3′ rev: 5′- AGTCAGGGTGCAGCGGG-3′), *STAT1A* (fw: 5′-CACCAGAGCCAATGGAACTT-3′ rev: 5′-ACAGAGCCCACTATCCGAGA-3′), *STAT1B* (fw: 5′-CTTTCCCTGACATCATTCGCA -3′ rev: 5′-AAGGCTGGCTTGAGGTTTGTA-3′), *EOMES* (fw: 5′-ACTGGTTCCCACTGGATGAG-3′ rev: 5′-CCACGCCATCCTCTGTAACT-3′), *PD-1* (fw: 5′-CAGTTCCAAACCCTGGTGGT-3′ rev: 5′-GGCTCCTATTGTCCCTCGTG-3′), *PD-L1* (fw: 5′-AGCAAAGTGATACACATTTGGAG-3′ rev: 5′-CCCCGATGAACCCCTAAACC-3′), *IDO* (fw: 5′-TGCTGTTCCTTACTGCCAAC-3′ rev: 5′-CGTCCATGTTCTCATAAGTCAGG-3′) and *CTLA4* (fw: 5′-CTCTGGATCCTTGCAGCAGT-3′ rev: 5′-GCCTCAGCTCTTGGAAATTG-3′). Reactions were performed for 50 cycles with an initial activation for 2 min at 98 °C, denaturation for 5 min at 95 °C and hybridisation and elongation for 10 min at 60 °C. Quantitative real-time PCR reactions were performed using the CFX-96 Real-Time PCR Detection System (Bio-Rad), and analysed via the CFX Manager Software (Bio-Rad Laboratories GmbH, Munchen, Germany). The relative expression level of specific transcripts was calculated with respect to the internal standard (HPRT). Expression levels were normalised to control lung tissues using ΔΔCT calculation. For comparison of the expression of different genes, efficiency-corrected calculation of relative gene expression, normalised with HPRT, was performed using the relative standard curve method.

Western blot analyses
---------------------

Western blots were performed with 30--50 *μ*g of protein. Polyacrylamide gel electrophoresis was performed at 80 V for 1.5 h. Proteins were then transferred to a nitrocellulose membrane (PAGEr Ex Gels, Lonza, Rockland, USA) at 200 mA for 45 min. After a washing step and blocking of the membrane for 1 h (5% milk powder, 0.1% Tween-20 in PBS) at room temperature, the primary antibody against pSTAT1 (Cell Signaling Technology, Danvers, MA\< USA) was applied and incubated overnight at 4 °C. The next day the membrane was washed and incubated with the HRP-conjugated secondary antibody, solved in blocking buffer, for 1 h at room temperature. After final washing steps, detection was performed using the Western Bright Quantum Western Blotting detection kit (Biozym Scientific, Oldendorf, Germany). For the visualisation of the western blot results, the Fluor Chem FC2 (Biozym Scientific) detection system was used.

Immunohistochemistry of CD8 on paraffin-embedded tissue sections
----------------------------------------------------------------

Immunohistochemistry was performed on paraffin-embedded sections. Before staining, paraffin was removed from the slides by incubation at 72 °C for 30 min and treatment with Roti-Histol (Carl Roth, Karlsruhe, Germany) three times for 10 min. The tissue sections were then rehydrated by immersion in ethanol-series with descending concentrations (100%, 95%, 70%) for 3 min each and in deionised water for 1 min. In the next step, a heat-induced antigen retrieval was performed. Slides were placed into a rack, containing 50 ml of 1 × Tris-EDTA and incubated at 120 °C for 5 min, at 85 °C for 10 s and at RT for 20 min using a pressure cooker. The slides were then washed in deionised water for 1 min. The tissue was surrounded with a hydrophobic barrier using a barrier pen (Dako, Hamburg, Germany). Peroxidase blocking solution (Dako) was then applied on the sections and incubated for 5 min at RT. Slides were washed with washing buffer for 5 min, incubated with primary antibody for 2 h at RT and washed with washing buffer for 5 min. Afterwards, slides were incubated with labelled polymer-HRP for 30 min at RT and washed with washing buffer for 5 min. again. Tissue sections were treated with DAB+Substrate and DAB+Chromogen solution for 10 min at RT. Slides were rinsed with Aqua dest carefully and treated with haematoxylin and eosin solution for 2 min. Slides were rinsed in Aqua dest for 1 min and two times in deionised water for 3 min. each. Sections were dehydrated by immersion in ethanol-series with increasing concentrations (70%, 95%, 100%) for 3 min each and treated with Roti-Histol two times for 5 min. Tissue sections were covered with cover plates using 1 or 2 drops of mounting media (Entellan, Merck, Darmstadt, Germany).

Immunohistochemistry of signal transducer and activator of transcription 1 (STAT1) on paraffin-embedded tissue sections
-----------------------------------------------------------------------------------------------------------------------

Deparaffination, rehydration and antigen retrieval was performed as described above. Afterwards, blocking solution (Zytomed Systems, Berlin, Germany) was applied on the sections and incubated for 5 min at RT. Slides were washed with washing buffer for 5 min and incubated with primary antibody to STAT1 (Santa Cruz, Dallas, TX, USA) overnight at RT. The next day slides were washed with washing buffer for 5 min, slides were incubated with Post Block reagent (Zytomed Systems) for 30 min at RT and washed with washing buffer for 5 min again. Tissue sections were treated with AP-Polymer reagent (Zytomed Systems) for 30 min at RT, washed with washing buffer for 5 min and incubated with Permanent AP Red (Zytomed Systems) for 10 min at RT. Slides were then carefully rinsed with Aqua dest and treated with haematoxylin and eosin solution for 1 min. Slides were rinsed in Aqua dest for 1 min and in deionised water for 5 min. Tissue sections were covered with coverslips using Aquatex (Merck).

Immunohistochemistry of STAT1 on cytospins
------------------------------------------

Cytospins were prepared using 100.000 A549 ADC cells, which were subsequently fixed by incubation with cold aceton for 10 min. The cytospins were surrounded with a hydrophobic barrier using a barrier pen (Dako). Afterwards, Zytomed blocking solution (Zytomed Systems) was applied on the sections and incubated for 5 min at RT. Slides were washed with washing buffer for 5 min, and incubated with primary antibody (Santa Cruz) for 2 h at RT and washed with washing buffer for 5 min. Afterwards, slides were incubated with Post Block Reagent (Zytomed Systems) for 30 min at RT and washed with washing buffer for 5 min again. Tissue sections were treated with AP-Polymer reagent (Zytomed Systems) for 30 min at RT, washed with washing buffer for 5 min and incubated with Permanent AP Red (Zytomed Systems) for 10 min at RT. Slides were then carefully rinsed with Aqua dest and nuclei were stained with haematoxylin solution for 1 min. Slides were rinsed in Aqua dest for 1 min and in deionised water two times for 3 min each. Tissue sections were covered with coverslips using Aquatex (Merck).

CD8^+^ T cell isolation
-----------------------

CD8^+^ T cell isolation was performed using magnetic anti-human CD8 Microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer\'s instructions or by FACS-sorting in cooperation with a facility service of the University of Erlangen (Core Unit Cell Sorting and Immunomonitoring, SFB 643). For that purpose, total cell suspensions were stained with anti-human CD8 PE antibody (BD Biosciences, Heidelberg, Germany) according to the surface staining protocol described below.

Flow cytometry analyses (FACS)
------------------------------

Flow cytometry analyses were performed with 1 × 10^6^ total cells per sample and staining. The cells were washed with PBS, followed by incubation (30 min., 4 °C, dark) with the respective mix of antibodies against surface proteins, solved in PBS (ad 80 *μ*l). After an additional washing step, the cells were fixed and permeabilised with Fixation/Permeabilisation solutions according to the manufacturer\'s protocol (eBioscience, San Diego, CA, USA) and incubated (30 min, 4 °C, dark) with antibodies against intracellular proteins, dissolved in Permeabilisation buffer (eBioscience; ad 80 *μ*l). After a final washing step with Permeabilisation buffer (eBioscience), the cells were resuspended in PBS+EDTA (Lonza, Cologne, Germany). For FACS analyses of surface markers alone, the cells were washed with PBS and resuspended in PBS+EDTA after incubation with the antibodies directed against antigen expressed on the cell membrane surface. No fixation and permeabilisation were performed in that case. The subsequent flow cytometry measurements were performed via FACS Calibur and analysed using Cell Quest Pro version 4.02 (BD Biosciences). The following antibodies were used during this study: anti-human CD4 FITC (eBioscience), anti-human CD8 Alexa Fluor 488 (eBioscience), anti-human CD11b FITC (eBioscience) and anti-human/mouse T-bet PE (BD Bioscience).

Flow cytometry analyses of phosphorylated STAT1
-----------------------------------------------

Single-cell suspensions were generated from a tumoral, peri-tumoral and a control lung sample of a patient with NSCLC. Total lung cells were carefully resuspended in RPMI media, containing FCS, Pen/Strep, *α*CD3 (2.5 *μ* ml^−1^)±IFN-*γ* (50 ng ml^−1^) and incubated at 37 °C for 20 min. Flow cytometry staining was performed with 1--1.5 × 10^6^ total cells per sample and staining. The cells were washed with PBS, followed by incubation (30 min., 4 °C, dark) with the respective master mix of antibodies against surface proteins, solved in PBS (ad 50 *μ*l). After an additional washing step, the cells were fixed by incubation with 300 *μ*l 2% PFA (30 min., 4 °C, dark). Afterwards, the samples were centrifuged, the PFA-solution was aspirated and the cells were incubated with 300 *μ*l of cold 90% methanol (30 min, 4 °C, dark). After another cell centrifugation and the aspiration of methanol solution, the cells were incubated with the PE-conjugated pSTAT1 antibody (BD Biosciences), solved in 50 *μ*l Permeabilisation buffer (BD Biosciences; 30 min., 4 °C, dark). After a final washing step with 200 *μ*l of Permeabilisation buffer (BD Biosciences), the cells were resuspended in PBS+EDTA (Lonza). The subsequent flow cytometry measurements were performed via FACS Calibur and analysed using Cell Quest Pro version 4.02 (BD Biosciences).

Co-culture and apoptosis assay
------------------------------

A small piece of the tissue sample from the tumoral region was resected and transferred into culturing medium overnight (RPMI+10% FCS+1% Penicilin/Strepomycin; no digestion or shredding were applied to the sample). The cellular outgrowth of this tumour sample was treated with collagenase seeded in new plate and grown overnight. The rest of the sample was subjected to collagenase digestion, together with the peri-tumoral sample and the control sample as well as a regional lymph node, for subsequent isolation of total cells and CD8^+^ T cells (in accordance to the procedure described above). The following day, tumoral cells were expanded from the piece of tumour tissue on the cell plate. The expanded tumour cells were harvested, counted and co-cultured with CD8^+^ T cells, isolated from the tumoral, peri-tumoral and the control area, respectively. 5 × 10^4^ tumour cells and 1 × 10^5^ CD8^+^ T cells from the respective region were cultured with 5 *μ*g ml^−1^ soluble anti-CD3 (BD Bioscience) and 2 *μ*g ml^−1^ anti-CD28 (BD Bioscience) for 24 h. Apoptosis assay was performed on the following day by staining the cells with APC Annexin V (BD Bioscience), propidium iodide (PI; BD Bioscience) and flow cytometry analysis were performed according to the manufacturer\'s protocol.

Statistical analysis
--------------------

Differences were evaluated for significance (*P*\<0.05) by the Student\'s two-tailed *t*-test for independent events (Excel, PC). Data are given as mean values±s.e.m.

Results
=======

Decreased T-bet expression in the tumoral regions of patients with NSCLC
------------------------------------------------------------------------

Here we isolated mRNA from the tumoral, peri-tumoral (2 cm around the tumour area) and the control lung region (taken at least 5 cm far away from the tumour border) of patients with ADC as well as SCC and analysed the expression of *TBX21* by real-time PCR. *TBX21* mRNA expression level was found downregulated in the tumoral region as compared with the peri-tumoral and control region of both ADC and SCC ([Figure 1A and B](#fig1){ref-type="fig"}). To examine the influence of T-bet downregulation on the progression of lung cancer, we correlated the mRNA expression of *TBX21* with the diameter of the lung tumour from the individual patients, finding a negative correlation between *TBX21* expression and the tumour size in patients with adenocarcinoma but not with SCC ([Figure 1C and D](#fig1){ref-type="fig"}). In confirmation of this, we found that the number of CD4^+^ and CD8^+^ T-bet^+^ T cells decreased in the tumoral area as compared with those found in the control area ([Figure 1H](#fig1){ref-type="fig"}).

IL-12 is a cytokine inducing IFN-*γ* and Th1 cells ([@bib17]). We therefore also analysed IL-12 production in the BALF of patients with NSCLC ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). However, here we could not detect this cytokine. This indicates that the Th1 defect could be secondary to a defect of IL-12 in patients with NSCLC.

Decreased IFN-*γ* in the tumoral region of patients with NSCLC
--------------------------------------------------------------

T-bet directly promotes the transcription of *IFNG* in Th1 and Tc1 cells and is in turn induced by IFN-*γ* via a positive feedback loop ([@bib27]; [@bib19]). To determine whether impaired expression of T-bet was associated with reduced expression of *IFNG* in the tumoral area of patients with NSCLC, we assessed mRNA expression levels of the Th1 cytokine IFN-*γ*. We observed a significant suppression of *IFNG* mRNA levels in the tumoral regions of patients with ADC and SCC as compared with the peri-tumoral and control regions ([Figure 1E and F](#fig1){ref-type="fig"}). The association of T-bet and IFN-*γ* expression in the lung tissue of patients with NSCLC was further confirmed by a significant positive correlation of *TBX21* and *IFNG* mRNA levels in all three analysed lung areas ([Figure 1G](#fig1){ref-type="fig"}).

Decreased perforin expression in the tumoral region of patients with NSCLC
--------------------------------------------------------------------------

Perforin is expressed by cytotoxic lymphocytes and released from secretory granules to form pores in target cells that allow serine protease granzymes to enter the cell and induce cell death ([@bib20]; [@bib28]). Besides IFN-*γ* expression, T-bet also controls the cytotoxicity of CD8^+^ T cells and is involved in the regulation of Perforin production ([@bib5]; [@bib16]). Therefore, we determined the mRNA expression of Perforin (*PRF1*) in tumoral, peri-tumoral and control lung tissue from patients with ADC and SCC. Comparable to our results for *TBX21* and *IFNG* expression, *PRF1* mRNA levels were significantly decreased in the tumoral area of ADC and SCC, suggesting impaired Tc1 responses ([Figure 2A and B](#fig2){ref-type="fig"}). Analysing the correlation between *PRF1* mRNA expression and the tumour diameter in patients with NSCLC, we found that although there is a tendency, suggesting that low expression of *PRF1* is associated with increased tumour diameters in patients with ADC similar to *TBX21*, the correlation is not statistically significant ([Supplementary Figure 1A and B](#sup1){ref-type="supplementary-material"}). Finally, we also found a significant positive correlation between *TBX21* and *PRF1* mRNA expression in the control as well as in the peri-tumoral and the tumoral region of patients with NSCLC ([Figure 2E](#fig2){ref-type="fig"}).

Decreased eomesodermin (EOMES) in the tumoral region of patients with SCC
-------------------------------------------------------------------------

Eomesodermin also known as T-box brain protein 2 encodes a transcription factor that is involved in the regulation of different developmental processes ([@bib14]). Besides T-bet, EOMES is also important for the development of effector CD8^+^ T cells ([@bib10]). Here we found *EOMES* mRNA significantly decreased in the tumoral region of patients with SCC ([Figure 2C and D](#fig2){ref-type="fig"}). Similar to T-bet, EOMES positively correlated with perforin (*PRF1*) mRNA expression in the control as well as in the peri-tumoral and the tumoral region of patients with NSCLC ([Figure 2F](#fig2){ref-type="fig"}). However, EOMES did not inversely correlate with the tumour load ([Supplementary Figure 1C and D](#sup1){ref-type="supplementary-material"}), neither did *EOMES* positively correlate with *IFNG* mRNA expression ([Supplementary Figure 1E](#sup1){ref-type="supplementary-material"}) in these patients with NSCLC.

Increased CD8^+^ T cell numbers with decreased Tc1 gene expression in the tumoral region of NSCLC
-------------------------------------------------------------------------------------------------

We next wondered if the overall numbers of CD8^+^ T cells are reduced in the tumoral region of patients with NSCLC. Therefore, we performed immunohistochemistry for CD8 on lung tissue histo-arrays from the control and tumoral region of four patients with lung ADC, four patients with SCC and from three control subjects without lung cancer ([Table 1](#tbl1){ref-type="table"}). Here we found a higher density of CD8^+^ T cells in the tumoral region of patients with lung ADC as compared with the control region as well as with samples from control subjects and with the tumoral region of SCC ([Figure 3A--D](#fig3){ref-type="fig"}). This result might indicate that the lung ADC is more immunogenic as compared with squamous carcinoma. We next studied the relative mRNA expression of *TBX21* and *PRF1* in CD8^+^ T cells, isolated from the lung tissue of NSCLC patients. We analysed CD8^+^ T cells infiltrating the tumoral, the peri-tumoral and the control region, finding that mRNA expression of these Tc1 genes was significantly decreased in CD8^+^ T cells isolated from the tumoral region as compared with the peri-tumoral and control region of patients with lung cancer ([Figure 3E and F](#fig3){ref-type="fig"}).

Decreased pSTAT1*α* in the tumoral region of patients with NSCLC
----------------------------------------------------------------

According to previous studies, *TBX21* expression can be induced by IFN-*γ* in a STAT1-dependent manner ([@bib19]; [@bib1]). To further analyse the putative alterations of the Th1 signalling pathway in NSCLC, we thus next assessed the protein levels of phosphorylated STAT1 in the tumoral, peri-tumoral and control lung areas of patients with ADC and SCC ([Figure 4A and B](#fig4){ref-type="fig"}).

In the control and peri-tumoral region of the lungs, we observed two bands, corresponding to the two isoforms of STAT1, which are generated by alternative splicing, STAT1*α* (91 kDa) and the C-terminally truncated STAT1*β* (84 kDa; [@bib26]; [@bib22]). Both isoforms are able to form homo (*α*/*α* or *β*/*β*) as well as heterodimers (*α*/*β*), to translocate to the nucleus and bind to IFN-*γ*-activated sites. However, STAT1*β* overexpression has been shown to inhibit STAT1*α* function and is thus suggested to negatively regulate the expression of IFN-*γ* responsive genes ([@bib23]). Here we found that the protein level of phosphorylated STAT1*α*-isoform was barely detectable in the tumoral lung region of both ADC and SCC as compared with the peri-tumoral as well as the control region ([Figure 4A, C and E](#fig4){ref-type="fig"}). By contrast, phosphorylated STAT1*β* was present in the tumoral, peri-tumoral and the control area of patients with ADC, whereas it could not be detected in the tumoral region of patients with SCC ([Figure 4B, D and F](#fig4){ref-type="fig"}).

Cellular distribution of pSTAT1 in the lung of patients with NSCLC
------------------------------------------------------------------

In the next step, we tried to understand the cellular localisation of pSTAT1 in the tumour microenvironment. To this aim, we performed FACS analysis using an antibody against pSTAT1 in tumoral, peri-tumoral and control lung cells isolated from a patient with NSCLC. Before staining, the cell suspensions were incubated at 37 °C in the presence or absence of IFN-*γ* for 20 min in order to induce STAT1 phosphorylation. We aimed to investigate phosphorylated STAT1 in different immunological cell subsets, such as CD4^+^ Th1 cells, CD8^+^ Tc1 cells and CD11b^+^ macrophages. CD4^+^pSTAT1^+^ cells and CD8^+^pSTAT1^+^ cells were gated on lymphocytes, whereas CD11b^+^pSTAT1^+^ cells were gated on big cells. Generally, we observed that the majority of pSTAT1^+^ cells in our experiment were CD11b^+^ macrophages, whereas only a small fraction of pSTAT1^+^ cells was CD4^+^ or CD8^+^ in the control, peri-tumoral and tumoral region of the lung ([Figure 4H](#fig4){ref-type="fig"}). Nevertheless, we found that the fraction of pSTAT1-expressing macrophages (CD11b) as well as CD4^+^ and CD8^+^ T cells decreased in the tumoral region as compared with the control as well as the peri-tumoral region of the lung of this patient with NSCLC ([Figure 4H](#fig4){ref-type="fig"}). By observing the pSTAT1^+^CD11b^−^ cells gated on big cells, we saw that their number increased in the tumoral region of this lung. We conclude that also tumour cells could contain pSTAT1 ([Figure 4H](#fig4){ref-type="fig"}).

We next assessed the mean fluorescence intensity of pSTAT1 gated on CD4^+^, CD8^+^ or CD11b^+^ cells from the tumoral, the peri-tumoral and the control lung area in the presence or absence of IFN-*γ*. With this approach, we observed a higher pSTAT1 level in CD4^+^ and CD8^+^ cells from the control lung area as compared with the peri-tumoral and the tumoral lung area of the NSCLC patient upon IFN-*γ* treatment, whereas this difference could not be observed in the absence of IFN-*γ* ([Figure 4G](#fig4){ref-type="fig"}). This allows the conclusion that CD4 and CD8^+^ T cells from the control lung area of patients with NSCLC may be more responsive to IFN-*γ* signalling, inducing STAT1 phosphorylation.

Taken together these data suggest that pSTAT1^+^ macrophages as well as IFN*γ*-responsive Th1 and Tc1 cells are mainly localised in the control and peri-tumoral region of these patients with NSCLC. Moreover, we suggest that the tumour cells themselves can contain pSTAT1.

STAT1 mRNA and protein levels in the lungs of patients with NSCLC
-----------------------------------------------------------------

We wondered if only the phosphorylation of STAT1 is changed in the tumoral area of NSCLC or if the two isoforms of STAT1 are differentially expressed in the three analysed regions of the tumour-bearing lungs. Therefore, we next assessed the mRNA levels of *STAT1A* and *STAT1B* in the tumoral, the peri-tumoral and the control region of patients with ADC and SCC, finding that there is no difference in the expression levels of *STAT1A* and *STAT1B* between the tumoral, the peri-tumoral and the control lung area of patients with ADC and SCC ([Figure 5A--D](#fig5){ref-type="fig"}). This observation was further confirmed by immunohistochemical (IHC) staining for STAT1 in a tissue array enclosing the tumoral and control region of most of the patients analysed by real-time PCR. After counting the STAT1-positive cells, no difference in STAT1^+^ cell numbers was observed between tissue sections from the control and the tumoral lung area of NSCLC patients ([Figure 5E](#fig5){ref-type="fig"} and [Supplementary Figure 1N and O](#sup1){ref-type="supplementary-material"}). Moreover, by observing the IHC staining for STAT1 at higher magnification, we observed that macrophages in the lung of patients with NSCLC as well as in control lungs were an important source of STAT1 ([Figure 5E](#fig5){ref-type="fig"}). We also observed that the tumour cells themselves expressed STAT1 and epithelial cells ([Figure 5E](#fig5){ref-type="fig"}). This observation was confirmed by IHC for STAT1 on the lung tumour ADC cell line A549 ([Figure 5F](#fig5){ref-type="fig"}).

In conclusion, the expression of STAT1 in tumour cells could explain why there is no overall decrease in STAT1 expression between the control *versus* the tumoral region, although the number of pSTAT1^+^CD11b^+^, pSTAT1^+^CD4^+^and CD8^+^ T cells decreased in the tumoral region of the lung of patients with NSCLC.

Programmed cell death 1 (PD-1), PD-L1 expression in the tumoral region of ADC as compared with SCC
--------------------------------------------------------------------------------------------------

The above data collectively indicate a decrease of Th1 and Tc1 markers in the tumoral region of patients with NSCLC. Programmed cell death 1 and its ligand PD-L1 are necessary for the regulation of the balance between T-cell activation and tolerance. The PD-1/PD-L1 pathway has previously been shown to contribute to tumour-mediated immune suppression and is thus recently being considered as an interesting target for clinical trials ([@bib13]). As it has also been shown that Th1 and Tc1 cells are targets for PD-1/PD-L1-mediated immune suppression ([@bib18]), we wanted to see if this pathway is differentially regulated in lung samples from patients with ADC and SCC. The overall expression of these two genes was not found differentially regulated in the different lung regions of patients with ADC. By contrast, in the tumoral region of SCC, unexpectedly, *PD-1* and *PD-L1* mRNA was found downregulated as compared with the control region ([Figure 6A and B](#fig6){ref-type="fig"}).

*IDO* mRNA expression in the lungs of patients with NSCLC
---------------------------------------------------------

Indoleamine 2, 3-dioxygenase (IDO) is another mediator of tumour immune tolerance, which causes T cell suppression. However, IDO is also known to be up-regulated in tumour cells in an IFN*γ* and STAT1-dependent manner ([@bib4]). We thus next analysed IDO expression in NSCLC. Here we found decreased expression of *IDO* mRNA only in the tumoral region of SCC but not in the ADC ([Figure 6C](#fig6){ref-type="fig"}). This could imply that the ADC tumour cells express more IDO as they express STAT1.

*CTLA-4* mRNA expression in the lungs of patients with NSCLC
------------------------------------------------------------

Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is an inhibitory immunoglobulin that is expressed on the surface of helper T cells. Moreover, CTLA-4 has been shown to be upregulated by regulatory T cells and has a role for their suppressive function ([@bib6]). The tumour microenvironment is characterised by high levels of inhibitory cytokines, such as IL-10 and TGF-*β*, which are able to induce regulatory T cells ([@bib21]; [@bib12]). We therefore next analysed the mRNA expression of the Treg surface marker CTLA-4 in NSCLC lung samples. However, we could not detect any significant differences at the mRNA level between the tumoral, the peri-tumoral and the control areas of patients with ADC or SCC ([Figure 6D](#fig6){ref-type="fig"}).

Relative increase of immunosuppressive genes *PD-1*, *PD-L1*, *IDO* and *CTLA-4* in the tumoral region of NSCLC
---------------------------------------------------------------------------------------------------------------

As we did not observe an upregulation of immunosuppressive genes in the tumoral region of NSCLC lung samples, we wondered how strong the expression of these genes is in relation to the mRNA levels of pro-inflammatory factors. To this aim, we did an efficiency corrected semi-quantitative PCR gene comparison. In patients with ADC, we found that the mRNA levels of the anti-inflammatory genes *PD-1*, *PD-L1*, *IDO* and *CTLA-4* are higher as compared with the pro-inflammatory genes *TBX21*, *IFNG* and *PRF1* in all three analysed lung regions. However, in the tumoral region of ADC, the balance of the expression level is further shifted towards the immunosuppressive genes. In patients with SCC, the mRNA levels of *CTLA-4* and *PD-1* are higher as compared with the pro-inflammatory genes *TBX21*, *IFNG* and *PRF1* only in the tumoral lung area, whereas in the control and the peri-tumoral area of SCC the relative expression of *IFNG* is higher than that of the tested immunosuppressive genes ([Figure 6E and F](#fig6){ref-type="fig"}).

Decreased cytotoxic activity of CD8^+^ T cells isolated from the tumoral region of lung carcinoma
-------------------------------------------------------------------------------------------------

We next asked whether the decreased expression of *PRF1* in the tumoral region would affect the cytotoxic activity of local CD8^+^ T cells. To address this issue, we isolated CD8^+^ T cells from the different lung carcinoma areas and co-cultured them with tumour cells from the respective patient. Afterwards, we assessed the numbers of apoptotic (Annexin V^+^) and necrotic (PI^+^) tumour cells by using an Annexin V/PI assay. We noted that CD8^+^ T cells from the control and peri- tumoral areas are able to induce tumour cell death in co-culture (PI^+^ cells), whereas no significant induction of cell death was detected after co-culture with CD8^+^ T cells from the tumoral area ([Figure 7A--D](#fig7){ref-type="fig"}). These findings indicated an impaired cytotoxic activity of intra-tumoral lung CD8^+^ T cells in patients with NSCLC, which can be relevant for therapeutic settings.

Discussion
==========

Current treatment modalities for lung cancer are limited and the identification of novel targets for therapy is of high relevance. In the present study, we analysed the local distribution and regulation of tumour-infiltrating immune cell subsets and the expression of their hallmark genes in lung tissue samples of patients suffering from NSCLC.

We thus analysed the expression of specific transcription factors and markers controlling the Th1 and Tc1 differentiation in the tumoral, the peri-tumoral as well as in the control region of patients with NSCLC. It is believed that the most potent antitumour effector cells are CD8^+^ CTLs producing IFN-*γ*. Thus, a majority of clinical cancer vaccination studies focusses on the activation of tumour-specific CD8^+^ T cells ([@bib11]).

Two major effector molecules of the granule-mediated cytolytic pathway, which are thought to be involved in tumour suppression, are granzyme B and Perforin. Perforin creates a membrane channel through which granzyme B is able to enter the target cell and to evolve its cytolytic function ([@bib9]). Consistently, we detected a downregulation of the mRNA levels of the Th1/Tc1 transcription factor, T-bet as well as of the Th1 and CTL effector molecules IFN-*γ* and Perforin in the tumoral region of the lungs of NSCLC patients, although the overall numbers of CD8^+^ T cells were increased in the tumoral area of patients with ADC and were not significantly changed in patients with SCC. This is in line with previous work that demonstrates a relationship between higher numbers of T-bet-positive intra-tumoral lymphocytes and a positive prognosis for patients with breast cancer ([@bib15]; [@bib31]) and the fact that T-bet was found to be required for anti-tumour immune responses in a murine model of lung cancer partially due to its ability to control intra-tumoral development of regulatory T cells ([@bib25]). Eomesodermin is, like T-bet, another transcription factor involved in CD8^+^ T cell development. Eomesodermin was found downregulated in the tumoral region of patients with SCC but not ADC. The finding that *EOMES* neither correlates with *IFNG* nor inversely correlates with the tumour size, although it does correlate with Perforin, in these patients, questions its relevance in the patho-mechanism of lung cancer as compared with T-bet. In fact, here we found a negative correlation between the size of the tumour and the mRNA level of *TBX21* in patients with ADC, which underlines the importance of T-bet-mediated immune responses for anti-tumour effects.

In accordance with these findings, we found that CD8^+^ T cells isolated from the tumoral region induce less tumour cell death as compared with those isolated from the control and peri-tumoral region of the same patient. We suppose that the increased cytotoxic activity of the CD8^+^ T cells, isolated from the control area was due to T-bet-induced Perforin expression, both found increased in CD8^+^ T cells sorted out from the control lung area, as compared with those from the tumoral area. These findings suggest an accumulation of Th1 and Tc1 cells with anti-tumour potential in the control lung region, surrounding the solid tumour of lung cancer patients. Based on these results, a possible approach for a potential therapeutical anti-tumour application could be an *in vitro* expansion of CD8^+^ T cells, isolated from the control lung area or from the PBMC of the individual patient, followed by adoptive transfer of the expanded cytotoxic T cells back into the patient, post surgery. Taken together, we identified characteristic alterations of the local immune landscape in tumour tissue of NSCLC patients that were characterised by an impairment of T-bet-associated Th1 and Tc1 immune responses.

In this study, we analysed two of the NSCLC subtypes separately to identify putative differences concerning the immune responses in patients with ADC and SCC. In a previously published work, we were already able to demonstrate that genes, which are associated with the Th17 cell type, such as *IL-6R*, *BATF* and *RORC* are differentially expressed in patients suffering from ADC and SCC ([@bib2]). Consistently, we could identify some differences between these two types of lung cancer in this study as well. Thus, we found increased numbers of CD8^+^ T cells in the tumoral area of patients with ADC as compared with SCC. Besides that, we found an association between the tumour size and the expression of *TBX21* and *PRF1* mRNA in patients with adeno- but not with SCC. Finally, we found that only the phosphorylation of STAT1*α*, but not STAT1*β*, was reduced in the tumoral area of patients with ADC, whereas we could not detect phosphorylation of neither of the two STAT1 isoforms in the tumoral region of SCC. Moreover, we observed decreased phosphorylation and thus activation of STAT1*α* in the tumoral lung region of patients with adeno- as well as with SCC, which is necessary for the transcription of Th1/Tc1 genes downstream of IFN-*γ*. Tumour infiltrating macrophages (TAMs) have previously been shown to stimulate tumour growth and metastasis in different kinds of cancer ([@bib30]). Here we identified macrophages infiltrating the lung of these patients as the major source of STAT1. STAT1 has been described as the transcription factor regulating colony-stimulating factor 1 (CSF-1) production. CSF-1 in turn induces TAM via CSF-1 receptor (CSFR) engagement. These data therefore support a central role of STAT1 in lung tumour especially with regard to TAM induction that need to be further investigated. Beside macrophages, also the tumour cells were found to express STAT1. Although we could not find any differential regulation of *IDO*, *PD-1* and *PD-L1* mRNA in the different regions of the ADC lung tissues, in the SCC *IDO*, *PD-1* and *PD-L1* were found significantly downregulated in the tumoral region, suggesting that these immunosuppressive factors could represent a better possible target for the therapy of the ADC subgroup. Nevertheless, semi-quantitative expression comparison between mRNA levels of Th1/Tc1 genes like *TBX21* and suppressive genes like *CTLA-4* and *PD-1* suggested a shift of the balance towards the suppressive genes in the tumoral lung region of both adeno- and SCC. The reason for the differential regulation of these genes in ADC and SCC still needs further investigation.

Altogether, these results indicate differences in the regulation of anti-tumour immune responses in patients with adeno- and SCC, meaning that in case of the development of an immunotherapy this fact should be considered and patients with these two types of lung cancer would eventually require different treatment.
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![**Reduced *TBX21* and *IFNG* mRNA expression in the tumoral region of NSCLC.** (**A** and **B**) qPCR-based expression analysis of *TBX21* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with adenocarcinoma (ADC) or squamous cell carcinoma (SCC; ADC: *N*~Control~=16, *N*~Peri-tumoral~=15, *N*~Tumoral~=16; SCC: *N*~Control~=17, *N*~Peri-tumoral~=17, *N*~Tumoral~=17). (**C** and **D**) Correlation between the tumour diameter and the *TBX21* mRNA expression in the control area of patients with ADC and SCC. (**E** and **F**) qPCR-based expression analysis of *IFNG* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=14, *N*~Peri-tumoral~=13, *N*~Tumoral~=14; SCC: *N*~Control~=16, *N*~Peri-tumoral~=16, *N*~Tumoral~=17). (**G**) Correlation between *TBX21* and *IFNG* mRNA levels in the control as well as in the peri-tumoral and the tumoral area of patients with non-small-cell lung cancer (NSCLC). (**H**) Flow cytometry analysis of T-bet^+^CD4^+^ and T-bet^+^CD8^+^ T cells gated on lymphocytes from the control, the peri-tumoral and the tumoral lung region of one representative patient with NSCLC. Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05; \*\**P=*0.01; \*\*\**P=*0.001.](bjc2015255f1){#fig1}

![**Reduced *PRF1* and *EOMES* mRNA expression levels in the tumoral region of NSCLC.** (**A** and **B**) qPCR-based expression analysis of *PRF1* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=15, *N*~Peri-tumoral~=14, *N*~Tumoral~=14; SCC: *N*~Control~=16, *N*~Peri-tumoral~=17, *N*~Tumoral~=16). (**C** and **D**) qPCR-based expression analysis of *EOMES* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=13, *N*~Peri-tumoral~=12, *N*~Tumoral~=15; SCC: *N*~Control~=16, *N*~Peri-tumoral~=14, *N*~Tumoral~=17). (**E**) Correlation between *TBX21* and *PRF1* mRNA levels in the control as well as in the peri-tumoral and the tumoral area of patients with NSCLC. (**F**) Correlation between *EOMES* and *PRF1* mRNA levels in the control as well as in the peri-tumoral and the tumoral area of patients with NSCLC. Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05; \*\**P*=0.01; \*\*\**P*=0.001.](bjc2015255f2){#fig2}

![**Increased numbers of CD8^+^ T cells in the tumoral lung region of patients with adenocarcinoma.** (**A**) IHC staining of CD8^+^ cells was performed on paraffin-embedded tissue sections from the control and the tumoral region of the lungs of patients with squamous cell carcinoma (*n*=4) and adenocarcinoma (*n*=4) as well as from the lungs of control subjects without lung tumour (*n*=3). (**B**--**D**) Bar charts represent CD8^+^ cell numbers counted on the tissue sections from the respective NSCLC patients as well as healthy controls. (**E**) qPCR-based expression analysis of *TBX21* mRNA in CD8^+^ T cells, isolated from lung tissue samples of the tumoral, peri-tumoral and control region of patients with NSCLC (*N*~Control~=4, *N*~Peri-tumoral~=4, *N*~Tumoral~=4). (**F**) qPCR-based expression analysis of *PRF1* mRNA in CD8^+^ T cells, isolated from lung tissue samples of the tumoral, peri-tumoral and control region of patients with NSCLC (*N*~Control~=3, *N*~Peri-tumoral~=3, *N*~Tumoral~=3). Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05.](bjc2015255f3){#fig3}

![**Reduced STAT1 phosphorylation in the tumoral region of NSCLC.** (**A**--**F**) Western blot analysis of pSTAT1 and actin expression in lung tissue samples from the tumoral, peri-tumoral and control region of patients with adenocarcinoma (ADC) (*N*~Control~=5; *N*~Peri-tumoral~=5, *N*~Tumoral~=5). Bar charts show mean values of the protein expression levels of pSTAT1 *α*-Isoform (**C** and **D**) and pSTAT1 *β*-Isoform (**E** and **F**) relative to actin levels in ADC and in SCC, respectively. (**G**) Flow cytometry analysis of pSTAT1^+^ cells in the tumoral, the peri-tumoral and the control lung region of one representative patient with NSCLC. pSTAT1 staining was performed with the lung cell suspensions after 20 min of incubation at 37 °C in the presence or absence of IFN-*γ*. pSTAT1^+^ cells were gated on CD4^+^, CD8^+^ or CD11b^+^ cells, respectively. (**H**) Flow cytometry analysis of pSTAT1^+^CD4^+^ and pSTAT1^+^CD8^+^ T cells gated on lymphocytes as well as pSTAT1^+^CD11b^+^ cells gated on big cells in the control, the peri-tumoral and the tumoral lung region of one representative patient with NSCLC. Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05.](bjc2015255f4){#fig4}

![**STAT1 *RNA* and protein expression in NSCLC lung samples.** (**A** and **B**) qPCR-based analysis of *STAT1A* mRNA expression in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC and SCC (ADC: *N*~Control~=16, *N*~Peri-tumoral~=15, *N*~Tumoral~=16; SCC: *N*~Control~=17, *N*~Peri-tumoral~=17, *N*~Tumoral~=17). (**C** and **D**) qPCR-based analysis of *STAT1B* mRNA expression in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC and SCC (ADC: *N*~Control~=15, *N*~Peri-tumoral~=13, *N*~Tumoral~=15; SCC: *N*~Control~=16, *N*~Peri-tumoral~=14, *N*~Tumoral~=16). (**E**) IHC staining of STAT1^+^ cells was performed on paraffin-embedded tissue sections from the control and the tumoral region of the lungs of patients with ADC and SCC as well as from the lungs of control subjects without lung tumour. (**F**) IHC staining was performed on cryospins of A549 human adenocarcinoma cell line. Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05.](bjc2015255f5){#fig5}

![**mRNA expression levels of T-regulatory cell signature genes in the lungs of patients with NSCLC.** (**A**) qPCR-based expression analysis of *PD-1* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=15, *N*~Peri-tumoral~=13, *N*~Tumoral~=15; SCC: *N*~Control~=16, *N*~Peri-tumoral~=15, *N*~Tumoral~=17). (**B**) qPCR-based expression analysis of *PD-L1* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=15, *N*~Peri-tumoral~=13, *N*~Tumoral~=15; SCC: *N*~Control~=16, *N*~Peri-tumoral~=15, *N*~Tumoral~=17). (**C**) qPCR-based expression analysis of *IDO* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=14, *N*~Peri-tumoral~=12, *N*~Tumoral~=15; SCC: *N*~Control~=16, *N*~Peri-tumoral~=15, *N*~Tumoral~=17). (**D**) qPCR-based expression analysis of *CTLA-4* mRNA in lung tissue samples from the tumoral, peri-tumoral and control region of patients with ADC or SCC (ADC: *N*~Control~=14, *N*~Peri-tumoral~=12, *N*~Tumoral~=15; SCC: *N*~Control~=16, *N*~Peri-tumoral~=15, *N*~Tumoral~=17). (E and F) qPCR-based analysis of *PRF1*, *IFNG*, *TBX21*, *CTLA-4, IDO*, *PD-L1*, *PD-1* mRNA levels in the tumoral, peri-tumoral and control lung regions of patients with ADC or SCC. Calculation of the efficiency corrected relative expression values for the different genes was performed using the relative standard curve method. Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05; \*\**P*=0.01.](bjc2015255f6){#fig6}

![**Increased killing capability of CD8^+^ T cells from the control area.** CD8^+^ T cells were isolated from the tumoral, peri-tumoral and control region of tissue samples from the lung of lung cancer patients. CD8^+^ cells were co-cultured with total cells from the tumoral region of the respective patient (tumour cells). Apoptosis and necrosis levels were evaluated by flow cytometry. Cells were double-stained with antibodies against Annexin V and PI. (**A**) Tumour cell gate and a representative flow cytometry plot of Annexin V *versus* PI staining is depicted. (**B**--**D**) Bar graphs show the mean percentages of Annexin V or PI single positive as well as Annexin V and PI double positive cells. Data are shown as mean values±s.e.m. using Student\'s *t*-test \**P*=0.05.](bjc2015255f7){#fig7}

###### Clinical data of patient cohort

  **Patient No.**    **Sample ID**  **Histological classification**    **Maximal tumour diameter (cm)**   **Grading**   **T**   **N**   **M**   **TNM stadium**  **Gender**    **Age (years)**   **Average smoking (P/Y)**   **Post-OP development of metastases**
  ----------------- --------------- --------------------------------- ---------------------------------- ------------- ------- ------- ------- ----------------- ------------ ----------------- --------------------------- ---------------------------------------
  1                      3-MP       ADC                                               5                       G3         2a       0       0           IB         Male                79                     60                                No
  2                      9-MP       ADC                                              2.7                      G2         1b       2       0          IIIA        Female              84                      0                                No
  3                      15-MP      ADC                                              2.5                      G3         1b       0       0           IA         Male                63                     100                               Yes
  4                      16-MP      ADC                                              4.6                      G3          3       0       0          II B        Female              70                     15                                No
  5                      17-MP      ADC                                              2.6                      G2          2       0       0           IB         Male                74                     70                                No
  6                      19-MP      ADC                                              6.5                      \#         2b       0       0           IIA        Female              55                     30                                No
  7                      20-MP      ADC                                              2.8                      G3         1b       0       0           IA         Male                65                     60                                No
  8                      22-MP      ADC                                               7                       G3         2b       1       0           IIB        Male                68                     82                                No
  9                      23-MP      ADC                                              4.5                      G2         2a       0       0           IB         Male                73                     75                                No
  10                     26-MP      ADC                                              1.3                      G3         1a       0       1           IV         Female              52                     50                                \#
  11                     27-MP      ADC                                              1.4                      G3         1a       0       0           IA         Female              70                     50                                No
  12                     28-MP      ADC                                              1.2                      G3         1a       0       0           IA         Male                76                     60                                No
  13                     32-MP      ADC                                              4.4                      G3         2a       2       0          IIIA        Female              60                     30                                Yes
  14                     34-MP      ADC                                              1.8                      G3          1       0       0           I A        Female              51                     45                                No
  15                     35-MP      ADC                                               3                       G3         1b       0       0           IA         Female              72                      0                                No
  16                     39-MP      ADC                                               6                       G3         2b       0       0           IIA        Male                65                     42                                No
  17                     40-MP      ADC                                              1.8                      G3         1a       1       0           IIA        Male                82                     100                               No
  18                     43-MP      ADC                                               4                       G3         2a       2       0          IIIA        Female              72                      0                                \#
  19                     44-MP      ADC                                              1.5                      \#         1a       0       0           IA         Male                53                     70                                No
  20                     45-MP      ADC                                              2.3                      G1         1b       0       0           IA         Male                78                      0                                No
  21                     1-MP       SCC                                              1.3                      G3         1b       0       0           IA         Male                80                     40                                No
  22                     2-MP       SCC                                              5.1                      G3         1a       0       0            0         Male                57                     40                                No
  23                     4-MP       SCC                                               2                       G3         1b       1       0           IIA        Female              53                     25                                \#
  24                     5-MP       SCC                                              10.5                     G2          3       0       0           IIB        Female              67                     50                                No
  25                     8-MP       SCC                                              5.5                      G3          3       0       0           IIB        Male                66                     30                                Yes
  26                     13-MP      SCC                                               3                       G3         1b       0       0           IA         Male                69                     50                                No
  27                     14-MP      SCC                                              1.9                      G2         1a       0       0           IA         Female              58                     30                                No
  28                     21-MP      SCC                                              2.5                      G1         1b       0       0           IA         Male                41                     10                                No
  29                     29-MP      SCC                                              3.7                      G3         1b       0       0           IIB        Male                74                     100                               No
  30                     30-MP      SCC                                              1.8                      G3         1a       0       0           IA         Female              70                     30                                No
  31                     36-MP      SCC                                              3.5                      G3         2a       1       0           IB         Male                74                     40                                No
  32                     37-MP      SCC                                              3.3                      G2         2a       1       0           IIA        Male                60                     45                                No
  33                     41-MP      SCC                                              1.3                      G3          3       1       0          IIIA        Male                70                     42                                No
  34                     42-MP      SCC                                              1.5                      G3         2b       1       0           IIB        Male                74                     40                                Yes
  35                     46-MP      SCC                                              9.5                      G3          3       1       0          IIIA        Male                60                     30                                \#
  36                     47-MP      SCC                                               6                       G3         2b       0       0           IIA        Male                64                     80                                No
  37                     48-MP      SCC                                               5                       G2         2b       0       0           IIA        Male                55                     20                                Yes
  38                      K5        Pneumotorax                                       0                        /          /       /       /            /         Male                45                     \#                                 /
  39                      K10       Pneumotorax                                       0                        /          /       /       /            /         Male                22                     \#                                 /
  40                      K12       Pneumotorax                                       0                        /          /       /       /            /         Female              21                     \#                                 /

Abbreviations: ADC=adenocarcinoma; SCC=squamous cell carcinoma.

\#No information available.

T-primary tumour: 0: No evidence of primary tumour; 1a: Tumour 2 cm or less in greatest dimension; 1b: Tumour more than 2 cm but not more than 3 cm in greatest dimension; 2a: Tumour more than 3 cm but not more than 5 cm in greatest dimension; 2b: Tumour more than 5 cm but not more than 7 cm in greatest dimension; 3: Tumour more than 7 cm. N-regional lymph nodes: 0: No regional lymph node metastasis; 1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension; 2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).

M-distant metastasis: 0: No distant metastasis; 1: Distant metastasis.

Histopathological grading: G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated.

[^1]: These two authors share the first authorship
